Blog
RSS FeedPosted by Michael Wonder on 29 Oct 2024
People with a rare form of blood cancer are set to benefit after NICE recommends new targeted therapy
29 October 2024 - Hundreds of people with a rare form of blood cancer could be set to benefit after NICE ...
Posted by Michael Wonder on 24 Oct 2024
Quizartinib dihydrochloride for the induction, consolidation and maintenance treatment of adults with newly diagnosed FLT3-ITD positive acute myeloid leukaemia
23 October 2024 - NICE has published final evidence-based recommendations on the use of quizartinib dihydrochloride (Vanflyta) for the induction, ...
Posted by Michael Wonder on 17 Oct 2024
First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended by NICE
17 October 2024 - For the first time, NICE has recommended a targeted treatment option for ALK positive non-small-cell lung cancer, ...
Posted by Michael Wonder on 08 Oct 2024
Fruquintinib for patients with previously treated metastatic colorectal cancer
8 October 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 02 Oct 2024
Elacestrant dihydrochloride for the treatment of patients with advanced, oestrogen receptor positive, ESR1 mutation positive, HER2 negative breast cancer after at least one endocrine treatment
1 October 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 02 Oct 2024
NICE ready to work with company to address uncertainty in evidence for elacestrant for advanced breast cancer
1 October 2024 - Today NICE is consulting on draft guidance that does not recommend elacestrant for treating a type of ...
Posted by Michael Wonder on 25 Sep 2024
Trifluridine with tipiracil hydrochloride in combination with bevacizumab for the treatment of patients with metastatic colorectal cancer after two systemic treatments (final guidance)
25 September 2024 - NICE has published final evidence-based recommendations on the use of trifluridine with tipiracil hydrochloride (Lonsurf) for ...
Posted by Michael Wonder on 19 Sep 2024
Daiichi Sankyo’s Vanflyta recommended by NICE for acute myeloid leukaemia
19 September 2024 - Daiichi Sankyo’s Vanflyta (quizartinib) has been recommended by NICE for certain cases of acute myeloid leukaemia. ...
Posted by Michael Wonder on 17 Sep 2024
Rucaparib camsylate for the maintenance treatment of patients with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (final guidance)
17 September 2024 - NICE has published final evidence-based recommendations on the use of rucaparib camsylate (Rubraca) for the maintenance ...
Posted by Michael Wonder on 12 Sep 2024
Futibatinib for previously treated patients with advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
11 September 2024 - NICE has published final evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 ...
Posted by Michael Wonder on 10 Sep 2024
Pembrolizumab for adjuvant treatment of patients with resected non-small-cell lung cancer
29 August 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 09 Sep 2024
Zolbetuximab in combination with chemotherapy for the first-line treatment of adults with unresectable advanced, claudin 18.2 positive HER2 negative gastric or gastro-oesophageal junction adenocarcinoma
9 September 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 05 Sep 2024
Adults with von Hippel-Lindau disease to benefit from new treatment
5 September 2024 - NICE has recommended belzutifan for some adults with von Hippel-Lindau disease, in final draft guidance, which could ...
Posted by Michael Wonder on 04 Sep 2024
Zanubrutinib for the treatment of patients with marginal zone lymphoma after anti-CD20-based treatment
4 September 2024 - NICE has published final evidence-based recommendations on the use of zanubrutinib (Brukinsa) for the treatment of ...
Posted by Michael Wonder on 29 Aug 2024
Pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy for the treatment of patients with advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma
29 August 2024 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) in combination with platinum- ...